GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Vivesto AB (OTCPK:OASMY) » Definitions » Cash Ratio

OASMY (Vivesto AB) Cash Ratio : 2.61 (As of Sep. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Vivesto AB Cash Ratio?

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. Vivesto AB's Cash Ratio for the quarter that ended in Sep. 2024 was 2.61.

Vivesto AB has a Cash Ratio of 2.61. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.

The historical rank and industry rank for Vivesto AB's Cash Ratio or its related term are showing as below:

OASMY' s Cash Ratio Range Over the Past 10 Years
Min: 0.03   Med: 1.04   Max: 6.76
Current: 2.22

During the past 13 years, Vivesto AB's highest Cash Ratio was 6.76. The lowest was 0.03. And the median was 1.04.

OASMY's Cash Ratio is ranked better than
79.3% of 1000 companies
in the Drug Manufacturers industry
Industry Median: 0.59 vs OASMY: 2.22

Vivesto AB Cash Ratio Historical Data

The historical data trend for Vivesto AB's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vivesto AB Cash Ratio Chart

Vivesto AB Annual Data
Trend Apr15 Apr16 Apr17 Apr18 Apr19 Apr20 Dec21 Dec22 Dec23 Dec24
Cash Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.46 2.47 6.40 3.37 2.22

Vivesto AB Quarterly Data
Jan20 Apr20 Jul20 Oct20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Cash Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.37 3.54 2.81 2.61 2.22

Competitive Comparison of Vivesto AB's Cash Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Vivesto AB's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vivesto AB's Cash Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Vivesto AB's Cash Ratio distribution charts can be found below:

* The bar in red indicates where Vivesto AB's Cash Ratio falls into.


;
;

Vivesto AB Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

Vivesto AB's Cash Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash Ratio (A: Dec. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=7.511/2.23
=3.37

Vivesto AB's Cash Ratio for the quarter that ended in Sep. 2024 is calculated as:

Cash Ratio (Q: Sep. 2024 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=3.997/1.529
=2.61

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vivesto AB  (OTCPK:OASMY) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.


Vivesto AB Cash Ratio Related Terms

Thank you for viewing the detailed overview of Vivesto AB's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Vivesto AB Business Description

Traded in Other Exchanges
Address
Gustav III:s Boulevard 46, 5th Floor, Solna, SWE, SE-169 73
Vivesto AB is a research and development company that develops new treatment options for patients suffering from difficult-to-treat cancer. The company's product development leverages its proprietary technology platforms to manufacture novel drug formulations that are intended to demonstrate improved properties in comparison with current alternatives, which can lead to a reduced side-effect profile and an expanded therapeutic area. The company has a portfolio of projects targeting cancer treatments.

Vivesto AB Headlines

From GuruFocus

Q2 2021 Oasmia Pharmaceutical AB Earnings Call Transcript

By GuruFocus Research 03-06-2024

Q4 2021 Oasmia Pharmaceutical AB Earnings Call Transcript

By GuruFocus Research 03-06-2024

Q4 2020 Oasmia Pharmaceutical AB Earnings Call Transcript

By GuruFocus Research 03-06-2024